The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2016 | ASCEND-1 and ASCEND-2: Ceritinib for ALK-rearranged NSCLC and baseline brain metastases
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses results from ASCEND-1 and ASCEND-2, two non-randomized phase 1/2 multicenter, open-label, single-arm trials evaluating the efficacy of ceritinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor, in patients with pretreated, ALK-rearranged non-small cell lung cancer (NSCLC) and baseline brain metastases.
